RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.
The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators